Navigation Links
Savient Provides Update on KRYSTEXXA(TM) BLA Resubmission Activities
Date:1/8/2010

EAST BRUNSWICK, N.J., Jan. 8 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today provided an update on its activities directed toward the resubmission of its Biologics License Application (BLA) for KRYSTEXXA(TM) (pegloticase) as a treatment for chronic gout in patients refractory to conventional therapy and reaffirmed its belief that it continues to be on track for the filing of the BLA resubmission for KRYSTEXXA in the first quarter of 2010.

The Company announced that:

  • It has completed the reversion to the manufacturing processes used to manufacture its pegloticase active pharmaceutical ingredient (API) drug substance for the pivotal Phase 3 clinical trials which the Company had committed to pursue during the September 2009 Type "A" meeting as its plan to address the concerns raised by the Food and Drug Administration (FDA) in the July 31, 2009 complete response letter. Three consecutive batches of pegloticase API drug substance were manufactured in late October 2009 at the Company's third party contract manufacturer (CMO) and were then manufactured into final KRYSTEXXA drug product in November 2009. All batches were placed on stability testing by early December 2009. This manufacturing process reversion included the successful return to the PEGylation concentration utilized in the manufacture of pegloticase API for the pivotal replicate Phase 3 clinical trials.
  • The Company has received from its third party testing laboratories the majority of the in-process and final release analytical test results performed on the three consecutive batches of pegloticase API drug substance and final drug product. These analytical tests are necessary to validate these batches as being comparable to the drug product used in the Phase 3 clinical trials to establish the safety and effic
    '/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results
2. Savient Pharmaceuticals Announces Closing of Public Offering and Exercise of Over-Allotment Option
3. Savient Pharmaceuticals Prices Underwritten Offering of Common Stock
4. Savient Pharmaceuticals Announces Proposed Public Offering of Common Stock
5. Savient Provides Update on Pegloticase BLA
6. Savient Announces FDAs Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients
7. Cephalon Provides Update on Regulatory Review of NUVIGIL for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
8. New Market Research Report from BioTrends Provides Insight on How Rheumatologists are Utilizing Biologic Agents in the Treatment of Rheumatoid Arthritis
9. Southridge LLC Provides Funding Through Private Equity Agreement with Imaging Diagnostic Systems, Inc.
10. New National Pharmaceutical Council Report Provides Guidance on Evaluating Comparative Effectiveness Studies
11. Simcere Pharmaceutical Group Provides Update on Jiangsu Yanshen
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014 ApolloDx™ today announced ... platform during a special event at the company,s office ... on September 5, 2014. The event, which will start ... ApolloDx website, www.apollodx.com .    "We ... said Jared Bauer , Co-Founder and Managing Partner ...
(Date:8/20/2014)... DIEGO , Aug. 20, 2014 Trovagene, ... diagnostics, announced today that results from two clinical studies ... conference for the Company,s urine-based diagnostic test for the ... The IPV conference is scheduled to take place in ... to 25 th . Additionally, a new U.S. ...
(Date:8/20/2014)... Phase I Trial of Plasma ... KalVista Pharmaceuticals ("KalVista"), an ophthalmology company with a ... it has begun a Phase I, First in Human, ... the treatment of DME. The study,s Principal Investigator is ... Joslin Diabetes Center; Harvard Medical School Department of Ophthalmology, ...
Breaking Medicine Technology:Trovagene Provides Update on Its Urine-Based HPV Test 2Trovagene Provides Update on Its Urine-Based HPV Test 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4
... conjunction with DURECT Corporation,s (Nasdaq: DRRX ) fourth ... listen to the conference call that will be broadcast live ... pm Eastern Time (1:30 pm Pacific Time). (Logo: ... the presentation will be available by accessing DURECT,s homepage at ...
... -- The SimplyGo Portable Oxygen Concentrator by Philips ... continuous flow and pulse does at a weight of only ... lightest weight continuous flow portable concentrator weighed in at a ... voltage meaning anywhere you go in the world you can ...
Cached Medicine Technology:SimplyGo Portable Oxygen Concentrator Now Available 2
(Date:8/21/2014)... 2014 The employees of Pharmica ... Washington Crossing, Pennsylvania on Thursday, August 7th to spend ... been looking for different ways that Pharmica could get ... with Pharmica Consulting. “When we heard that we could ... we jumped at the opportunity.” , Pharmica spent their ...
(Date:8/21/2014)... 21, 2014 Sometimes you have to lose the ... new book “From Zero to a Hundred: Finding My Purpose through ... story of surviving a broken family, a childhood of gang violence ... who you were created to be,” Roy said. “I didn’t give ... I know my purpose today of helping others overcome their trials.” ...
(Date:8/21/2014)... Michael E. Steuer , local doctor in ... the Bluff City with recent philanthropy at local synagogue. “The ... United States,” says friend and Rabbi David Julian of Or ... as providing in-house for the needy and teaching Hebrew to ... the local synagogue. And to remain close with the development ...
(Date:8/21/2014)... Drake University’s Phi Gamma Delta (FIJI) and ... cancer research, according to Billy Cundiff, President of Colleen’s ... for the Cleveland Browns, says the money raised by ... Dream Foundation and will fund research to be conducted ... Division of Gynecologic Oncology at the University of Iowa’s ...
(Date:8/21/2014)... Recently, BambooIndustry.com, one of the most famous ... new range of hand scraped bamboo floorings ... an Autumn special offer for these elegant items. According ... a discounted price, up to 25% off; the promotion ... , Providing natural looks and available in different varieties, ...
Breaking Medicine News(10 mins):Health News:Pharmica Spends the Day Helping to Preserve Washington Crossing Historic Park 2Health News:Zero to a Hundred: True Story of Escaping Death to Meet Life 2Health News:Drake University’s Phi Gamma Delta (FIJI) and Colleen’s Dream Foundation Donate $10,000 to the University of Iowa’s Holden Cancer Center to Fight Ovarian Cancer 2Health News:Drake University’s Phi Gamma Delta (FIJI) and Colleen’s Dream Foundation Donate $10,000 to the University of Iowa’s Holden Cancer Center to Fight Ovarian Cancer 3Health News:Cheap Hand Scraped Bamboo Floorings Recently Unveiled by BambooIndustry.com 2
... Anderson Hospital administration and their ED process improvement ... the ED Patient Throughput Team at ... The ED Patient Throughput Team, responsible for reducing wait times ... three finalists to receive the award for their excellence in ...
... higher in moms-to-be who snore, study finds , THURSDAY, June ... more likely to develop gestational diabetes, new research has found. ... survey when they were between six and 20 weeks pregnant, ... that pregnant women who were frequent snorers -- defined as ...
... ... him uniquely qualified to lead NVCI , ... Las Vegas, NV (PRWEB) June 11, 2009 -- Stephen J. ... as Chairman of the Board for the Nevada Cancer Institute (NVCI) effective July 1, ...
... As a result of the economic climate, high-technology and ... in addition to extending cost controls for their current ... Aon Consulting,s Radford, a leading provider of compensation intelligence ... , , (Logo: http://www.newscom.com/cgi-bin/prnh/20041215/CGW049LOGO ) , ...
... had best results in study , THURSDAY, June 11 (HealthDay ... diabetes, may also help non-diabetic obese people lose weight when ... Researchers divided 152 obese men and women (with a body-mass ... 241 pounds) into two groups. About 25 percent of the ...
... Researchers at Nationwide Children,s Hospital and Johns Hopkins University ... highly expressed in normal tissues but lost in diseased ... (miRNA) are a class of small RNA molecules that ... in gene expression and in maintaining normal cell development ...
Cached Medicine News:Health News:Anderson ED Team Receives Pinnacle Award for Excellence in Customer Service 2Health News:Anderson ED Team Receives Pinnacle Award for Excellence in Customer Service 3Health News:Frequent Snoring in Pregnancy Could Signal Blood Sugar Trouble 2Health News:Nevada Cancer Institute Names Stephen J. Cloobeck Chairman of the Board 2Health News:Nevada Cancer Institute Names Stephen J. Cloobeck Chairman of the Board 3Health News:Bonus Payout Trends and Continuing Cost Controls Reflect Challenging Business Climate, Says Aon Consulting's Radford 2Health News:Bonus Payout Trends and Continuing Cost Controls Reflect Challenging Business Climate, Says Aon Consulting's Radford 3Health News:Bonus Payout Trends and Continuing Cost Controls Reflect Challenging Business Climate, Says Aon Consulting's Radford 4Health News:Diabetes Drug Byetta May Aid Weight Loss in Obese Patients 2Health News:Study shows promise for new cancer-stopping therapy 2
... easy-to-use 3800 and 3900/P pulse oximeters ... the proprietary clinical patient motion algorithm ... improved performance:, ,The 3800 and ... rigorous environmental/ mechanical stress testing such ...
... The Acuity LT Central Monitoring Station provides ... and ready to go right out of ... surveillance in specific care areas rather than ... ICU. As patient-to-caregiver ratios continue to climb ...
... 3800 and 3900/P pulse oximeters are ... proprietary clinical patient motion algorithm from ... performance:, ,The 3800 and 3900 ... environmental/ mechanical stress testing such as ...
... Researchers., ,S/5 Collect and S/5 Collect4 provides ... collect data from Datex-Ohmeda monitors. Data can be ... intervals. With S/5 Collect you have ability to ... interface cable or connect directly from S/5 Central. ...
Medicine Products: